These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy. Comella CL; Morrissey M; Janko K Neurology; 2005 Apr; 64(8):1450-1. PubMed ID: 15851743 [TBL] [Abstract][Full Text] [Related]
8. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias. Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640 [TBL] [Abstract][Full Text] [Related]
9. [The role of dopaminagonists in the treatment of Parkinson's disease]. Ransmayr G Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084 [TBL] [Abstract][Full Text] [Related]
11. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect. Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340 [TBL] [Abstract][Full Text] [Related]
12. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio). Stocchi F; Marconi S Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107 [TBL] [Abstract][Full Text] [Related]
13. [Prevention and treatment of fluctuations in patients with Parkinson's disease]. Ludin HP; Surber Ch Praxis (Bern 1994); 2006 Dec; 95(51-52):2013-8. PubMed ID: 17294589 [TBL] [Abstract][Full Text] [Related]
14. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Manson AJ; Turner K; Lees AJ Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062 [TBL] [Abstract][Full Text] [Related]
15. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table. Grosset K; Needleman F; Macphee G; Grosset D Mov Disord; 2004 Nov; 19(11):1370-4. PubMed ID: 15389984 [TBL] [Abstract][Full Text] [Related]
16. Pergolide in the treatment of patients with early and advanced Parkinson's disease. Bonuccelli U; Colzi A; Del Dotto P Clin Neuropharmacol; 2002; 25(1):1-10. PubMed ID: 11852289 [TBL] [Abstract][Full Text] [Related]
17. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease. Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141 [TBL] [Abstract][Full Text] [Related]
18. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia. Stacy M; Galbreath A Clin Neuropharmacol; 2008; 31(1):51-6. PubMed ID: 18303491 [TBL] [Abstract][Full Text] [Related]
19. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. Colzi A; Turner K; Lees AJ J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668 [TBL] [Abstract][Full Text] [Related]
20. The management approaches to dyskinesia vary from country to country. Woitalla D; Mueller T; Russ H; Hock K; Haeger DA Neuroepidemiology; 2007; 29(3-4):163-9. PubMed ID: 18043000 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]